How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Chemicals and Materials · Forecast 2027–2033
Perilla Leaves Extract Market
- By Form: Powder, Liquid Extract, Oil, Capsules
- By Application: Food & Beverage, Pharmaceuticals, Cosmetics, Nutraceuticals, Animal Feed
- By Extraction Method: Solvent Extraction, Supercritical CO2 Extraction, Cold Pressing, Steam Distillation
- By End-Use Industry: Dietary Supplements, Personal Care Products, Functional Foods, Traditional Medicine
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Powder leads By Form at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 9 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 260 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 9 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the Perilla Leaves Extract Market report
A complete, evidence-based study - 11 chapters and 109 sections covering market size, segmentation across 4 axes, regional analysis and 9 company profiles, forecast to 2033.
Segmentation covered
Form 4
Application 5
Extraction Method 4
End-Use Industry 4
Companies profiled
Xi'an Natural Field Bio-Technique Co. Ltd.
Nanjing Zelang Medical Technology Co. Ltd.
Hunan Nutramax Inc.
Jiangxi Nutra-Pharma Co. Ltd.
Xi'an Lyphar Biotech Co. Ltd.
Shandong Jianyuan Biotechnology Co. Ltd.
Xi'an Sost Biotech Co. Ltd.
Xi'an Green Spring Technology Co. Ltd.
Xi'an Biof Bio-Technology Co. Ltd.
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
9 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Xi'an Natural Field Bio-Technique Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Nanjing Zelang Medical Technology Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Hunan Nutramax Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Jiangxi Nutra-Pharma Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Xi'an Lyphar Biotech Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Shandong Jianyuan Biotechnology Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Xi'an Sost Biotech Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Xi'an Green Spring Technology Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.196 →Xi'an Biof Bio-Technology Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,472M by 2033 · 10.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Powder41.8
- Liquid Extract16.9
- Oil20.7
- Capsules20.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,151M → $2,674M · 11.1%
Europe$802.2M → $1,674M · 9.6%
Asia Pacific$732.4M → $1,554M · 9.9%
Latin America$453.4M → $892.1M · 8.8%
Middle East and Africa$348.8M → $718.0M · 9.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.942026
9.962027
9.982028
9.992029
10.002030
10.012031
10.012032
10.042033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Xi'an Natural Field Bio-Technique Co. Ltd.16.4
- Nanjing Zelang Medical Technology Co. Ltd.18.2
- Hunan Nutramax Inc.9.6
- Jiangxi Nutra-Pharma Co. Ltd.10.0
- Xi'an Lyphar Biotech Co. Ltd.6.1
- Shandong Jianyuan Biotechnology Co. Ltd.11.8
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Form19.8%
Application22.4%
Extraction Method30.0%
End-Use Industry27.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.6
- Europe22.3
- Asia Pacific20.7
- Latin America11.9
- Middle East and Africa9.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Xi'an Natural Field Bio-Technique Co. Ltd. | 86 | 98 | 97 | 93 | 94 | 78 | 91 |
| Nanjing Zelang Medical Technology Co. Ltd. | 86 | 89 | 92 | 68 | 89 | 87 | 85 |
| Hunan Nutramax Inc. | 71 | 71 | 83 | 84 | 70 | 74 | 76 |
| Jiangxi Nutra-Pharma Co. Ltd. | 62 | 63 | 78 | 60 | 68 | 64 | 66 |
| Xi'an Lyphar Biotech Co. Ltd. | 65 | 64 | 67 | 75 | 53 | 68 | 65 |
| Shandong Jianyuan Biotechnology Co. Ltd. | 49 | 55 | 60 | 57 | 55 | 66 | 57 |
| Xi'an Sost Biotech Co. Ltd. | 48 | 51 | 64 | 65 | 66 | 57 | 59 |
| Xi'an Green Spring Technology Co. Ltd. | 42 | 40 | 58 | 55 | 51 | 46 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Xi'an Natural Field Bio-Technique Co. Ltd.
- Nanjing Zelang Medical Technology Co. Ltd.
- Hunan Nutramax Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Xi'an Natural Field Bio-Technique Co. Ltd. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Nanjing Zelang Medical Technology Co. Ltd. | ◐ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Hunan Nutramax Inc. | − | ◐ | ✓ | ◐ | ◐ | ◐ |
| Jiangxi Nutra-Pharma Co. Ltd. | − | ◐ | ◐ | ◐ | ◐ | ✓ |
| Xi'an Lyphar Biotech Co. Ltd. | ◐ | ◐ | ◐ | ✓ | − | ◐ |
| Shandong Jianyuan Biotechnology Co. Ltd. | ◐ | − | − | ◐ | − | ◐ |
| Xi'an Sost Biotech Co. Ltd. | − | − | ◐ | ◐ | − | − |
| Xi'an Green Spring Technology Co. Ltd. | − | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Xi'an Natural Field Bio-Technique Co. Ltd.91
2Nanjing Zelang Medical Technology Co. Ltd.85
3Hunan Nutramax Inc.76
4Jiangxi Nutra-Pharma Co. Ltd.66
5Xi'an Lyphar Biotech Co. Ltd.65
6Xi'an Sost Biotech Co. Ltd.59
7Shandong Jianyuan Biotechnology Co. Ltd.57
8Xi'an Green Spring Technology Co. Ltd.49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Xi'an Natural Field Bio-Technique Co. Ltd.Nanjing Zelang Medical Technology Co. Ltd.
Challenger1
Strong scale, closing on the leaders.
Hunan Nutramax Inc.
Contender4
Focused players with pockets of strength.
Jiangxi Nutra-Pharma Co. Ltd.Xi'an Lyphar Biotech Co. Ltd.Shandong Jianyuan Biotechnology Co. Ltd.Xi'an Sost Biotech Co. Ltd.
Niche1
Specialists in a single segment or region.
Xi'an Green Spring Technology Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Form in North America, then scale across Perilla Leaves Extract Market — a $425M beachhead inside a $7.41B market.
Beachhead (SOM)$425Mobtainable near-term
Serviceable (SAM)$2.82Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Powder
Best fit — highest urgency & budget in Form.
Economic buyer76 fit
Liquid Extract
Strong fit — clear ROI and a fast path to value.
End user68 fit
Oil
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Form in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Extraction Method
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Form leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Perilla Leaves Extract Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified21%
Evaluation13%
Closed-won7%
$19.2KCAC
$74KLTV
3.8:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Perilla Leaves Extract Market is a resilient opportunity — $2.03B by 2033, compounding at 4.3%.
TAM · 2025$1.45Btoday
TAM · 2033$2.03Bforecast
CAGR4.3%2027–2033
Cumulative$15.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.03BTotal addressable market
SAM$792MServiceable available market
SOM$168MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.3% CAGR
Demand compounds through 2033, outpacing GDP across Form.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Form moving from early to mainstream — durable secular demand.
Consolidation upside
9+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.03BLarge & growingTAM by 2033 at 4.3% CAGR
$792MServiceable nowreachable with today’s model
$168MBeachhead winobtainable near-term share
9+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.59BBear2.8% CAGR
$2.03BBase4.3% CAGR
$2.60BBull5.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Perilla Leaves Extract Market — a $4.89B market by 2033. Plan: grow share from 7.4% to 12.4%.
Market size · 2033$4.89Btotal addressable
Market CAGR11.5%2027–2033
Target share12.4%from 7.4% today
Revenue ambition$606Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.4% | 12.4% | Ahead |
| Revenue | $341M | $606M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 30.2% | 42.5% | On track |
| Customer retention | 84.7% | 95.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Form
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Form share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $82M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Form leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Perilla Leaves Extract Market conversation — a $1.06B market you can size, segment and defend in minutes.
Market size · 2033$1.06Btotal opportunity
Growth6.6%CAGR to 2033
Addressable buyers1,037+accounts in scope
Typical ROI5.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Form
Goal Grow share in Form
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.6×return on cost, year one
< 2 mopayback period
$59K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
9+players profiled in this market
Coverage includes
Xi'an Natural Field Bio-Technique Co. Ltd.Nanjing Zelang Medical Technology Co. Ltd.Hunan Nutramax Inc.Jiangxi Nutra-Pharma Co. Ltd.Xi'an Lyphar Biotech Co. Ltd.Shandong Jianyuan Biotechnology Co. Ltd.Xi'an Sost Biotech Co. Ltd.Xi'an Green Spring Technology Co. Ltd.+1 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Perilla Leaves Extract Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Perilla Leaves Extract Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Chemicals and Materials · scroll →Electrical Sheet Molding Compound (SMC) Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportSelenium Metal Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportParaXylene Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportRoad Sealant Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportRoad Marking Materials Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportElectrical Safety Rubber Matting Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportRoad Marking Glass Beads Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportElectrical Safety Gloves Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportN-octyl Mercaptan (CAS 111-88-6) Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportN-Methyldiethanolamine (N-MDEA) Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportN-Methyldiethanolamine (MDEA) Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportNitrous Oxide Gas Market
Nitrous Oxide Gas Market is valued at USD 950 Million in 2025 and is expected to reach USD 1.2 …
$950M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.